The influence of the lipophilicity of 7-oxoacyl-L-alanyl-D-isoglutamines on their immunorestoration activity in vivo

European Journal of Medicinal Chemistry

Volumn 31, Issue 11, 1996, Pages 927-933

  Sollner, M ^a   Pecar S ^a   Stalc A ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b LEK   (Slovenia)

Author keywords

Desmuramyldipeptide; Immunomodulating activity; Immunorestoration; Lipophilicity

Indexed keywords

CYCLOPHOSPHAMIDE; DIPEPTIDE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; FEMALE; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; LIPOPHILICITY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION;

EID: 0029845471     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(97)89858-3     Document Type: Article

References (27)

1. 1 Adam A, Lederer E (1984) Med Res Rev 4, 111-152
2. 2 Bachang G (1989) Tetrahedron 45, 6331-6360
3. 3 Boulanger Y, Tu Y, Ratovelomanana V (1992) Tetrahedron 48, 8855-8868
4. 4 Fermandjian S, Perly B (1987) Car Res 162, 23-32
5. 5 Pristovšek P, Kidrič J, Hadži D (1995) J Chem Inf Comput Sci 35, 633-639
6. 6 Akasaki M (1988) Drug Res 38, 976-977
7. 7 Zidek Z (1994) Agents Actions 42, 163-166
8. 8 Werner GH, Floc'h F, Milignore-Samour D (1986) Experientia 42, 521-531
9. 9 Milignore-Samour D, Bouchaudon J, Floc'h F (1980) Life Sci 26, 883-888
10. 10 Parant AM (1987) In: Immunopharmacology of Infectious Diseases: Vaccine Adjuvants and Modulators of Non-Specific Resistance (Majde JA, ed) Alan R Liss, Inc, New York, 235-244
11. 11 Titov VM, Meshcheryakova EA, Balashova TA, Andronova TM, Ivanov VT (1995) Int J Pept Prot Res 45, 348-355
12. 12 Pečar S, Kikelj D, Urleb U et al (1993) US Patent 5 231 216
13. 13 Pečar S, Sollner M, Urleb U et al (1991) Eur Patent Application 91116356.6
14. 14 Sollner M, Kotnik V, Pečar S et al (1993) Agents Actions 38, 273-280
15. 15 Sollner M, Pečar S, Povšič L, Štalc A (1996) In: Peptides in Immunology (Schneider CH, ed) Wiley, Chichester (in press)
16. 16 Sollner M, Pečar S, Povšič L, Štalc A (1995) Pharm Pharmacol Lett 5, 38-41
17. 17 Hünig S, Lücke E, Benzing E (1958) Chem Ber 91, 129-133
18. 18 LeFrancier P, Bricas E (1967) Bull Soc Chim Biol 49, 1257-1271
19. 19 Handschumacher E (1992) In: Pharmacological Basis of Therapeutics (Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds) McGraw-Hill International Editions, New York, 1264-1276
20. 20 Frey BM (1993) Therapeutische Umschau 50, 71-76
21. 21 Matsumoto M, Tamura M, Matsubara S et al (1991) Microbiol Immunol 35, 461-474
22. 22 Pakhomova EN, Bykov VL (1994) Zh Mikrobiol Epidemiol Immunobiol 1, 14-16
23. 23 Brawner DL, Mori M (1992) J Infect Dis 166, 578-579
24. 24 Rekker RF, Mannhold R (1992) Calculation of Drug Lipophilicity. VCH, Weinheim
25. 25 Desforges JF, Rutherford CJ, Piro A (1979) N Engl J Med 301, 1212-1222
26. 26 Bicker U, Friedberg KD, Hebold G, Mengel K (1979) J Infect Dis 139, 389-395
27. 27 Shioiri T, Ninomya K, Yamada S (1972) J Am Chem Soc 94, 6203-6205